Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients
NCT02297763Phase 3
Key facts
- Status
- Unknown
- Start
- Mar 2015
- Primary completion
- Sep 2016
- Sponsor
- Seoul National University Hospital
- Modality
- Small Molecules
- Drugs
- quetiapine
- Conditions
- delirium
01
Overview
Phase 3, randomised trial in delirium comparing quetiapine with placebo (2 arms). Primary endpoint: Development of delirium within 14 days after admitting to ICU. Status: unknown.
02
Design
2 arms- Study design
- Randomized
quetiapine
quetiapine 12.5mg (bwt <50kg) or 25mg (bwt >= 50kg) provided as liquid form
placebo
100mg of corn starch melted in 10cc water
03
Who it enrols
Adults 19 years or older admitted to the medical ICU with an anticipated stay of >72 hours. Excludes pregnant/breastfeeding women, patients with active delirium, prior use of anti-psychotic drugs, severe bradycardia, alcohol intoxication, or renal/hepatic failure.
04
Endpoints
Primary
Development of delirium within 14 days after admitting to ICU
Secondary
Duration of delirium occurring within 14 days after admitting to ICU
Length of stay in ICU and hospital
60 days in hospital mortality
Duration of mechanical ventilation in ICU
Beyond the preview
Go deeper on NCT02297763.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02297763.